Neurocrine Biosciences Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
Neurocrine Bio. (NBIX) PT Raised to $100 at Baird After Another Beat for Ingrezza
May 1, 2018 7:15 AM EDTBaird raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $84.00) while maintaining an Outperform rating following another strong quarter for Ingrezza.
Analyst Brian Skorney commented, "Investor fears about a quarter of declining sequential growth turned out to be unfounded as... More
